Navigation Links
Amylin Pharmaceuticals Comments on Shareholder 13-D Filing
Date:1/29/2009

SAN DIEGO, Jan. 29 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) confirmed today that it has reviewed an amended 13-D filing with the Securities and Exchange Commission from Amylin shareholder Icahn Capital LP and affiliated funds announcing their intent to nominate a slate of five directors to stand for election at the Company's 2009 annual meeting. Amylin has not yet received the required notice with respect to this action.

Amylin's Corporate Governance Committee is engaged in a process to recommend a slate for election at the Company's annual meeting. It is reviewing potential nominees suggested by shareholders as part of that process, including two individuals previously discussed with representatives of the Icahn funds. Once the process has been completed, Amylin's Board of Directors will formally recommend a slate of nominees that it believes will act in the best interest of all shareholders.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Amylin Pharmaceuticals Reports 2008 Financial Results
2. Amylin Pharmaceuticals to Webcast Year-End Results
3. Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
4. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
5. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
6. Lilly and Amylin Set Date and Time for Conference Call
7. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
8. Amylin Pharmaceuticals Reports First Quarter Financial Results
9. Amylin Pharmaceuticals Reports 2007 Financial Results
10. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
11. Amylin Pharmaceuticals to Present at Research & Development Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business Management Association (RBMA) ... annual awards, now in their 12th year, are among the most prestigious in radiology ... 2016, the awards were retooled to recognize achievements in both large budget (over $5,000) ...
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic ... Center for Shamanic Healing and Spiritual Awakening, proudly presents her Sacred Peru ... This sacred and spiritual journey during the Summer Solstice will also be ...
(Date:3/24/2017)... ... 24, 2017 , ... The law firm of Enea, Scanlan & Sirignano, ... Westchester resident Lauren C. Enea has joined the firm as an associate attorney. Ms. ... practice in elder law, Medicaid planning and applications, and Wills, Trusts and Estates. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding ... God #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true communion with ... Walk with God #TruthwithGrace” is the creation of published author Lea Michelle Johnson, ...
(Date:3/23/2017)... ... 23, 2017 , ... In 2016 the World Health Organization declared the Zika ... million Zika-related cases in the Americas within the next year. Lyme disease is one ... year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne illnesses ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... PORTLAND, Oregon and PUNE, India , March 24, ... Market Research, titled, "Spine Bone Stimulators Market: Global Opportunity Analysis and Industry Forecast, ... and is projected to reach $724 million by 2022, growing at a CAGR ... ... Allied Market Research Logo ...
(Date:3/24/2017)... 2017  Zymo Research Corp., also known ... Inc., who designs, manufactures and distributes liquid ... teams Zymo Research,s DNA methylation detection and ... products with Hamilton,s high-throughput automation platforms. Zymo ... microbiomics and RNA isolation for use on ...
(Date:3/24/2017)... 24, 2017 Research and Markets has ... U.S.: Consumer Strategies" report to their offering. ... Pain Management ... and treat their physical pain, emphasizing consumer survey analysis, including ... sufferers and adults who have selected illnesses/conditions strongly associated with ...
Breaking Medicine Technology: